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Abstract  
Objective:  Acute-on-chronic liver failure (ACLF) is associated with dysfunctional circulating 
monocytes whereby patients become highly susceptible to bacterial infections. Here we identify 
the pathways underlying monocyte dysfunction in ACLF and investigate whether metabolic 
rewiring reinstates their phagocytic and inflammatory capacity.  
Design: Following phenotypic characterization, we performed RNA sequencing on 
CD14+CD16- monocytes from ACLF and decompensated alcoholic cirrhosis patients. 
Additionally, an in vitro model mimicking ACLF patient-derived features was implemented to 
investigate the efficacy of metabolic regulators on monocyte function.   
Results: Monocytes from ACLF patients featured elevated frequencies of IL-10-producing 
cells, reduced HLA-DR expression and, impaired phagocytic- and oxidative burst capacity. 
Transcriptional profiling of isolated CD14+CD16- monocytes in ACLF revealed upregulation 
of an array of immunosuppressive parameters and compromised antibacterial- and antigen 
presentation machinery. In contrast, monocytes in decompensated cirrhosis showed intact 
capacity to respond to inflammatory triggers. Culturing healthy monocytes in ACLF plasma 
mimicked the immunosuppressive characteristics observed in patients, inducing a blunted 
phagocytic response and metabolic program associated with a tolerant state. Metabolic rewiring 
of the cells using a pharmacological inhibitor of glutamine synthetase, partially restored the 
phagocytic and inflammatory capacity of in vitro-generated- as well as ACLF patient-derived 
monocytes. Highlighting its biological relevance, the glutamine synthetase/glutaminase ratio of 
ACLF patient-derived monocytes positively correlated with disease severity scores. 
Conclusion:  In ACLF, monocytes feature a distinct transcriptional profile, polarized towards 
an immunotolerant state and altered metabolism. We demonstrated that metabolic rewiring of 
ACLF monocytes partially revives their function, opening up new options for therapeutic 
targeting in these patients.  
  
Summary Box 
1. What is already known about this subject? 
 Monocyte dysfunction during ACLF is a well-described phenomenon 
 Singular factors such as MerTK or prostaglandin E2 have been implicated as 
potential mechanisms responsible for the suppressive status of monocyte during 
ACLF syndrome, however the overarching pathways that drive and sustain these 
disease-associated defects are not fully understood. 
2. What are the new findings? 
 Extensive characterization of monocytes from ACLF patients support a 
transcriptional, functional and metabolic switch towards immunotolerant state.  
 The transcriptional signature of ACLF patient-derived monocytes was distinct from 
that obtained from decompensated cirrhosis patients. 
 Feeding glutamine into the TCA cycle by using a pharmacological inhibitor of 
glutamine synthetase (GLUL), restored the phagocytic and inflammatory capacity 
of monocytes from ACLF patients.  
 Underscoring the biological relevance of this finding, we detected a positive 
correlation between GLUL/GLS ratio and MELD disease severity scores. 
 
3. How might it impact on clinical practice in the foreseeable future? 
 This study demonstrates that pharmacological regulation of metabolic programs 
partially restored the dysregulated monocyte function in ACLF. 
 These results may open new avenues for the development of therapeutic strategies 
to restore monocyte function in ACLF.  
Introduction 
Cirrhosis is the end result of chronic liver disease where persistent inflammation and stellate 
cell activation leads to collagen deposition, fibrosis, disruption of the intrahepatic venous flow 
and the development of portal hypertension [1]. Initially, the disease course may be 
asymptomatic, but if the insult persists, it may progress to decompensated cirrhosis with 
development of ascites, variceal bleeding and encephalopathy.  However, at any moment during 
the disease course a precipitating event can trigger rapid deterioration of liver function and 
organ failure, referred to as acute-on-chronic liver failure (ACLF) associated with high in-
hospital mortality rates, approaching 70% [2–6].  Importantly, ACLF is often precipitated by 
bacterial infections, which in turn may initiate a cascade of events resulting in multiple organ 
failure, irreversible septic shock and death [7,8]. The reason why the immune system in 
cirrhosis is defective and patients prone to infections is only partly understood.  One reason 
may be that the immune paralysis observed in cirrhosis is the result of exhaustion of circulating 
innate immune cells such as monocytes by continuous exposure to, and activation by damage-
associated molecular patterns (DAMP’s) released from the necrotic liver and from bacterial 
products translocation from the gut [9,10].  
 
Circulating monocytes are central players in the host innate immune defense against invading 
pathogens since they can interpret the extent of the microbial threat and raise an appropriate 
inflammatory response to contain the infection [11,12]. Following clearance, it is equally 
important that regulatory mechanisms are initiated to counteract excessive inflammation. 
Macrophages for instance are known for their plasticity in adopting either an inflammatory- or 
regulatory phenotype [13–15]. During the course of ACLF however, it is unclear whether 
patients succumb to infection due to a failure of monocytes/macrophages to sufficiently dampen 
the production of pro-inflammatory mediators leading to septic shock and organ damage, or 
whether they trigger a prolonged anti-inflammatory response rendering the patient incapable to 
respond to secondary infections. Nevertheless, studies taking a snap-shot of ACLF monocyte 
function at a given time, have confirmed the presence of a suppressive monocyte phenotype 
with reduced HLA-DR surface expression, antigen presentation capacity as well as impaired 
ability to secrete pro-inflammatory cytokines in response to bacterial components [16–19]. 
Although singular factors such as MerTK or prostaglandin E2 have been implicated as potential 
mechanisms responsible for monocyte dysfunction during ACLF syndrome [18,19], the 
overarching pathways that drive and sustain these disease-associated defects are not fully 
understood.  
The functional phenotype of monocytes/macrophages is highly regulated at both transcriptional 
and metabolic levels [20,21]. To exert their immunological functions, they can metabolize a 
variety of carbon substrates [22,23], and the nature of the metabolic program involved is 
critically associated with their activation status [24–26]. For example, pro-inflammatory 
macrophages consume glucose and heavily rely on glycolysis for ATP generation. Additionally, 
they exhibit a “broken” tricarboxylic acid (TCA) cycle, allowing accumulation of citrate and 
succinate. On the other hand, anti-inflammatory monocytes/macrophages maintain an intact 
TCA cycle and favor fatty acid oxidation, as a mode of ATP production [26–28]. In this study, 
the aim was to obtain a comprehensive view of the transcriptional profile of monocytes from 
ACLF patients and to investigate whether their molecular signature correlated with a functional 
and metabolic switch towards a suppressive phenotype. More importantly, we investigated 
whether metabolic rewiring of the cells using pharmacological inhibitors that channel glutamine 
into the TCA cycle, could restore ACLF monocyte dysfunction. These results may provide new 
insights into fundamental disease mechanisms.  
  
Materials and methods  
Patient characteristics 
For this study we recruited healthy controls, decompensated alcoholic cirrhosis, and ACLF 
patients diagnosed at the University hospital of Leuven between July 2013 to May 2017. 
Patients with alcoholic liver disease were identified and prospectively included at first contact 
in the emergency room (ER), the liver ward or the medical intensive care unit. Patients that 
used antibiotics or corticosteroid therapy during the 6 weeks preceding admission were not 
considered for inclusion in the study.  Patients with concomitant other liver diseases including 
viral hepatitis were excluded from participation. Blood was collected for study purposes before 
initiating other therapy. Blood and urine cultures were obtained, ascites fluid collected for 
analysis and a chest X-rays performed to exclude infections and pulmonary infiltrates as per 
standard of care. Patients with ACLF were classified according to the Consortium on Chronic 
Liver Failure–Sequential Organ Failure Assessment [CLIF-SOFA] classification [4]. Written 
informed consent was obtained from all patients or their designated family members and the 
study protocols were approved by the Ethical Commission UZ / KU Leuven (S54588). 
 
Plasma cytokine measurements 
Custom Meso Scale Discovery V-plex assays (Gaithersburg, MD) were used to determine 
plasma cytokine (IL-6, IL-8, IL-10 and TNF and chemokine (CCL2 and CCL3) levels. All 
measurements were performed in duplicate according to manufactures instructions.  
 
Phenotypic analysis of monocyte subsets and intracellular cytokine determination 
Peripheral blood mononuclear cells (PBMCs) were isolated and stained with the following 
antibodies:  CD3, CD19, CD56, CD14, CD16, HLA-DR (eBioscience, San Diego, CA) and 
matching isotype controls. Flow cytometric data acquisition was performed on a Gallios flow 
cytometer (Beckman Coulter, Analis, Belgium) and analyzed using FlowJo software [29]. For 
intracellular staining, PBMCs were stimulated with LPS and brefeldin A (eBioscience), for 18 
h and then stained with the same surface antibody cocktail as described above followed by the 
addition of Cytofix/Cytoperm (eBioscience) and anti-human IL-10 (BD Biosciences, 
Erembodegem, Belgium). 
 
Monocyte isolation and culture 
Blood was collected from healthy donors and ACLF patients in heparin-coated tubes (BD 
Biosciences). Immediately after collection, CD14+ monocytes were isolated from the PBMC 
fraction using a negative selection procedure according to the manufacturer’s specifications 
(Dynabeads untouched human monocyte kit, Invitrogen, Lennik, Belgium). Monocytes were 
cultured in RPMI medium containing antibiotics and further supplemented either with plasma 
from healthy donors or plasma from ACLF patients to give a final concentration of 20% by 
volume. Patient plasma used in these experiments represent a pool of 4 donors with ACLF grade 
2. Plasma was heat-inactivated (56°C for 30 min) and passed through a 0,22 µM filter prior to 
use. Following a 16-hour incubation time (37°C, 5 % CO2), the cells were harvested for 
transcriptional analysis or functional assessment of their phagocytic capacity as described 
below. 
 
Monocyte phagocytic- and oxidative burst capacity following exposure to E. coli 
The phagocytic and oxidative burst capacity of human monocytes were assessed as previously 
described [30].  Briefly, 100 µl heparinized peripheral blood was incubated for 1 hour at 37°C 
with pH-rodoRed-labeled E. coli bacteria (Invitrogen), previously opsonized with E. coli 
BioParticles®opsonizing reagent (Invitrogen). This was followed by the addition of the 
fluorogenic substrate rhodamine (20 min at 37°C) and staining for human monocyte markers. 
Flow cytometric data acquisition was performed as described above. 
 
RNA isolation and RNA-sequencing analysis 
RNA was isolated from freshly isolated monocytes, and from monocytes cultured in the 
presence or absence of ACLF plasma for 12 hours. RNA quantity and quality was measured, 
and samples meeting RNA integrity criteria were used for NextGeneration RNA-Sequencing 
(NGS) analysis using Illumina NextSeq instrument (detailed description in supplements). 
Sequencing and initial processing of the raw data was performed by the Nucleomics Core 
Facility, VIB, Leuven. Sequencing data are available at the Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE93265.  
 
Data analysis 
After preprocessing, reads were aligned to the reference genome of Homo sapiens (GRCh37.73) 
and a generalized linear model was fitted (described in supplements). Two types of analysis 
were performed: 1) Unpaired analysis between CD14+ monocytes from ACLF patient’s vs 
healthy controls (reflecting the ex vivo transcriptional profile) and 2) Paired analysis of CD14+ 
monocytes cultured in the presence or absence of ACLF plasma for 12 hours (reflecting an in 
vitro simulation of acute ACLF). The individual results were combined, the average calculated 
and the resulting p-values were computed. A gene was considered differentially expressed if a 
2log fold change >+1 or <-1 and a corrected p < 0.05 (see supplemental text for more detail).  
The genes differentially expressed in the same direction within both ex vivo ACLF patient 
samples as well as in vitro following monocyte exposure to ACLF plasma were used as input 
in the software packet Webgestalt (http://www.webgestalt.org). As read-out we analysed 
GO:Biological Processes (http://geneontology.org/), to explore the ex vivo patient samples. 
Alternatively, KEGG Pathways was used to explore the pathways involved following in vitro 
exposure of CD14+ monocytes to ACLF serum, (http://www.genome.jp/kegg/pathway.html).  
 
Live-cell real-time phagocytosis assay 
Isolated CD14+CD16- monocytes were plated onto 96-well clear flat-bottom polystyrene tissue-
culture treated microplates and allowed to adhere. Monocytes were cultured in RPMI 1640 
medium containing antibiotics and further supplemented either with plasma from healthy 
donors or plasma from ACLF patients at a final concentration of 20% by volume (see above). 
In some instances the cells were treated with Methionine sulfoximine at the indicated 
concentrations. pHrodo® pathogen bioparticles were added at indicated concentrations and the 
plates were transferred into a humidified incubator (37°C, 5%, CO2) and measured in real time 
using an IncuCyte Zoom imager (Satorius). Four images per well from three technical replicates 
were taken every 2 hours using a 10× objective lens and then analyzed using the IncuCyte™ 
Basic Software.  
 
Real-Time qPCR 
cDNA was synthesized using SuperScript II reverse transcriptase and random hexamer primers 
(Invitrogen/Life Technologies, USA). The PCR reaction was carried out in a mixture that 
contained appropriate sense- and anti-sense primers and a TaqMan MGB probe in Taq-Man 
Universal PCR Master Mixture (Applied Biosystems, Foster City, USA). Beta-2-microglobulin 
was used as housekeeping gene. qRT-PCR amplification and data analysis were performed 
using the Lightcycler 96 (Roche Applied Science, Penzberg, Germany). Each sample was 
assayed in duplicate. The ΔΔCq method was used to determine relative gene expression levels. 
 
Statistical analysis 
Group comparisons were performed using Kruskal-Wallis with Dunn’s correction for multiple 
testing or Mann-Whitney-Wilcoxon rank sum tests where appropriate. Spearman correlation 
was used to determine associations between variables. Statistical analyses were performed 
using JMP® version 11.0.0 (SAS Institute, Inc, Cary, NC) and SigmaPlot 12.0 (Systat Software, 




ACLF monocyte subset distribution, phenotype and cytokine response differ from 
decompensated cirrhosis patients 
Patients with ALCF are highly susceptible to infections and monocytes represent the first line 
of defense against pathogens entering the systemic circulation. Failure of monocytes to respond 
to danger signals may be due to an over production of immunosuppressive factors and/or the 
induction of a tolerant state. To identify the mechanisms that play a role in monocyte 
dysfunction during ACLF, we evaluated the expression of characteristic immunosuppressive 
markers such as intracellular IL-10 or surface expression of HLA-DR as read-out for their 
antigen presentation capacity. We specifically investigated whether these features from ACLF 
monocytes were different from those observed in decompensated cirrhosis patients. The clinical 
characteristics as well as circulating biochemical and immunological parameters of the patient 
cohort are documented in Supplemental Table 1 and Supplemental Figure 1. Flow cytometric 
analysis of monocyte distribution showed a significant decrease in the classical monocyte 
subset and expansion of the intermediate monocyte population (Figure 1A). Further, indicative 
of a decreased activation status, all monocyte subsets expressed lower levels of surface HLA-
DR. The latter observation was most pronounced in monocytes from ACLF patients (Figure 
1B). Additionally, we assayed intracellular IL-10 production following LPS exposure and 
detected elevated numbers of IL-10 producing monocytes within the intermediate monocyte as 
well as the classical monocyte subsets from ACLF patients, suggesting an elevated 
immunosuppressive function (Figure 1C).  
 
ACLF monocytes feature a distinctive immunosuppressive transcriptional profile 
To obtain an in-depth understanding of the molecular signatures responsible for this 
dysfunctional response, we performed a transcriptomic analysis of classical monocytes as the 
most abundant monocyte subset. CD14+ cells from ACLF patients (n=9), -decompensated 
cirrhosis patients (n=4) and -healthy controls (n=5) were freshly isolated with a negative 
selection strategy whereby CD16+ cells were additionally depleted along with all other 
unwanted cell types to avoid granulocyte contamination (see materials and methods for full 
description). Notably, ACLF grade 2 patients were included for this purpose to ensure 
homogeneity within this experimental group whereby the disease status can be very dynamic 
(see supplemental Table 2 for patient characteristics). Gene Ontology analysis to assess the 
biological processes involved revealed that the up-regulated genes from decompensated 
cirrhosis monocytes predominantly associated with immune response or leukocyte activation 
(Figure 2A). Conversely, biological pathways promoting immunological processes and cell 
activation were associated with the down-regulated genes in ACLF patient monocytes (Figure 
2B). Although there was an overlap of differentially regulated genes between these two 
conditions (not shown), the comparison of ACLF monocyte profiles to that of decompensated 
cirrhosis patients, unveiled unique differences of ACLF as disease entity. In this regard, the 
immunosuppressive nature in ACLF is further highlighted since the majority of the down 
regulated genes involve immune response processes (Figure 2C). 
 
Focusing specifically on subsets of immune-related genes illustrated that patient- as well as 
healthy monocytes cluster together, indicative of their distinct gene expression profiles. Heat 
maps of markers characteristically expressed by pro-inflammatory monocytes/macrophages 
(M1-like) were predominantly repressed (Figure 2D). These include cytokines and their 
receptors (TNFa, IL15, IL15R, IL23A, IL1B), chemokines (CCL4, CXCL9, CXCL10), co-
stimulators of antigen presentation (CD80, CD83) as well as transcription factors (STAT1). In 
sharp contrast, anti-inflammatory markers (M2-like) were largely overexpressed in monocytes 
from ACLF patients (Figure 2E). We observed a number of scavenger receptors (CD163, 
MRC1, CD36, MARCO), growth factors (HGF), suppressive cytokines (IL10), chemokines 
(CCL22) as well molecules involved in phagocytosis of apoptotic cells (MERTK, TGM2) and 
markers M2-like surface phenotype (MS4A4A) to be upregulated. In line with previous reports 
[31,32], we detected an increased frequency of MerTK-positive cells with a macrophage-like 
morphology in the liver tissue ACLF- compared to decompensated patients (Supplemental 
Figure 3). Furthermore, ACLF monocytes featured dampened expression of a battery of antigen 
presentation molecules (HLA), as well as co-activator (CIITA), molecular scaffold (TAP2) and 
molecules needed for proper folding and trafficking of MHC class II (CD74) (Supplemental 
Figure 2). Conversely, a number of heat-shock proteins (HSPA1A, HSPA1B, HSPA1L, HSPA6) 
which act as chaperones for proper folding and transport of newly synthesized polypeptides, 
were specifically upregulated within ACLF monocytes (Supplemental Figure 2). Combined, 
our data reveal that the extent of the immunosuppressive status of ACLF monocytes goes 
beyond what has been documented before and implicate major defects in their potential to 
mount pro-inflammatory responses and raise T-cell reactivity against pathogens (Figure 1B).  
 
Defective antibacterial response of ACLF monocytes 
We next aimed to evaluate whether immune dysfunction in ACLF translates into a defective 
functional capacity of monocytes to detect, engulf and respond to infection. To investigate 
monocyte ability to detect and recognize bacteria, we evaluated basal surface expression of both 
TLR2 and TLR4 on classical monocytes from the different patient groups. Interestingly, both 
decompensated cirrhosis patients as well as ACLF patients portrayed dampened expression 
levels of these markers (Figure 3A & 3B). We further assessed the ex vivo phagocytic and 
oxidative burst capacity of these cells following exposure to E. coli.  In line with defective 
bacterial recognition, monocytes isolated from both decompensated as well as ACLF patients 
featured a significantly impaired phagocytic capacity, although this defect was most prominent 
in patients with ACLF (Figure 3C). Monocytes from ACLF patients also featured a clear 
defective oxidative burst response, following interaction with E.coli (Figure 3D). To further 
identify the underlying pathways leading to this functional defect we investigated differentially 
regulated genes related to the antibacterial and oxidative burst response of monocytes 
originating from ACLF patients (see schematic representation of the components involved 
within Figure 3E). Notably, we detected dampened expression of IRF8, a prominent regulator 
of monocyte/macrophage pro-inflammatory- and anti-bacterial function. Dampened expression 
levels of IRF8 may implicate a defective ability to activate transcription of constituents of the 
NADPH oxidase complex, a key component of the oxidative burst response [33]. Nevertheless, 
the activity of the subunits within the NADPH oxidase complex can be regulated in different 
ways including at the level of post-translational modification. In this regard, we observed 
significantly lower levels of protein kinase C (PRKCE) within ACLF monocytes, suggesting 
that the defective oxidative burst may be partially related to inadequate phosphorylation of 
NADPH oxidase subunits. Furthermore, we detected the upregulation of Rnf145, a E3 ubiquitin 
ligase that negatively regulates gp91phox steady-state protein levels. Combined, our data 
highlight a number of mechanisms that may explain the functional defect of ACLF patients to 
respond to- and eradicate infections. 
 
Monocytes cultured with ACLF plasma mimic functional and transcriptional disease 
characteristics 
In order to explore the possibilities of reversing monocyte dysfunction, we devised an ACLF 
disease-mimicking in vitro model whereby freshly isolated CD14+ monocytes from healthy 
donors were cultured for 16 hours either in the presence of pooled plasma (20% v/v) from ACLF 
grade 2 patients or normal human plasma (Figure 4A). We first evaluated whether freshly 
isolated healthy CD14+ monocytes exposed to pooled ACLF grade 2 plasma in vitro, exhibit a 
transcriptional profile similar to that observed in monocytes obtained from ACLF patients. 
Indeed, the transcriptional signature obtained mimicked that of monocytes obtained from ACLF 
patients, showing a clear elevation of anti-inflammatory (M2-like), but only a partial dampening 
of inflammatory (M1-like) markers at 16 hours after exposure (Illustrated by the heat maps 
within Figure 4B & C). In line with the previous data, qPCR- and multiplex immune assay 
showed that ACLF plasma triggered a clear induction of anti-inflammatory parameters (IL-10 
and/or MerTK) while a tendency to dampen pro-inflammatory mediators (TNF IL-8) was 
observed in cultured monocytes (Figure 4D, E, F &G). Finally, to verify whether ACLF plasma-
conditioned monocytes also portrayed a  defective phagocytic activity we evaluated their ability 
to engulf gram-negative pHrodo-labeled E.coli particles over time using the IncuCyte Zoom 
system. The data indicate that ACLF plasma blunted the phagocytic capacity of healthy donor-
derived monocytes (Figure 4H). Of note, this defect in bacterial uptake only became apparent 
after 8-16 hours following conditioning of the cells in ACLF plasma. Interestingly monocytes 
cultured in the presence of ACLF plasma featured a similar defective capacity to engulf gram-
positive pHrodo-labeled S. aureus particles (Supplementary Figure 4). Combined, this 
observation strongly supports the hypothesis that circulating plasma derived factor(s) in ACLF 
plasma induce an ACLF-like phenotype in healthy donor derived monocytes. 
 
Metabolic rewiring and promoting TCA cycle metabolism, restores the phagocytic 
capacity of in vitro generated- as well as monocytes from ACLF patients 
Mounting evidence suggests that immune-suppressive cells exhibit unique metabolic 
requirements [33,34]. In particular, they maintain an intact TCA cycle and favor oxidative 
metabolism, especially fatty acid oxidation, as a mode of ATP production. Similar to what has 
been described for M2 macrophages, ACLF-conditioned monocytes also featured low 
glycolysis activity with lower expression of glycolytic enzymes (HK1, PGK1, PFKM, ENO2) 
(Figure 5A & Supplemental Figure 5). Glutamine, on the other hand can be catabolized thereby 
fueling the TCA cycle (Fig. 5A) [35]. We next argued that continued glutamine anabolism 
through glutamine synthetase (GLUL) may be responsible for the sustained suppressive 
phenotype of ACLF monocytes and we therefore implemented a strategy to redirect glutamine 
into the TCA cycle by inhibiting its enzyme activity. Hereto we tested the ability of the inhibitor 
of glutamine synthetase, methionine sulfoximine (MSO), to restore the phagocytic capacity of 
ACLF-plasma-conditioned monocytes (the concept thereof can be visualized in Figure 5B). 
Strikingly, treatment of monocytes cultured in the presence of ACLF plasma with MSO 
triggered a dose-dependent increase in their ability to phagocytose E. coli bioparticles (Figure 
5C). Considering the importance of the above findings, we reanalyzed the expression levels of 
parameters involved in glutamine metabolism within ACLF patient monocytes. More 
specifically, we calculated the ratio of glutamine anabolism over catabolism by assessing 
GLUL and GLS1 expression levels. Interestingly, the data clearly indicate an elevated 
GLUL/GLS ratio for monocyte originating from ACLF patients compared to healthy 
counterparts (Figure 5D). To improve our understanding of the significance of these findings, 
we investigated possible correlations of the GLUL/GLS ratio with survival or MELD scores of 
the patients. Importantly our data show that the GLUL/GLS ratio positively correlated with 
disease severity in ACLF patients (Figure 5E). Treatment of ACLF patient-derived monocytes 
with MSO similarly improved their capacity to recognize and engulf bacteria (Figure 5F). 
Finally, treatment of patient monocytes with MSO inhibited IL-10 production while promoting 
the production of the pro-inflammatory cytokine, TNFα (Figure 5G & H). 
  
Discussion 
Bacterial infection is one of the most common precipitating events in ACLF that may initiate 
multi-organ failure. The mechanisms and pathways responsible for failure of the host innate 
immune system to respond to bacterial infections in ACLF are only partly understood. Here we 
demonstrate that monocytes from ACLF patients show a broad range of innate immune defects, 
which extend beyond what has been previously documented. This monocyte 
immunosuppressive signature in ACLF is clearly different from decompensated cirrhosis  
supporting ACLF as a distinct clinical entity. We further demonstrate the importance of 
metabolic rewiring in establishing the monocyte phenotype in ACLF and showed that 
promoting glutamine fuelled TCA cycle metabolism within monocytes, improved their 
defective phagocytic and inflammatory function.  
 
In our study we observed that ACLF monocytes displayed profound defects in ex vivo 
phagocytic and oxidative burst capacity following exposure to E. coli (Fig 3E) that could be 
recapitulated by exposing healthy monocytes to ACLF plasma (Fig 4G) suggesting a specific 
defect in anti-bacterial function. We specifically focused on constituents of the Nox2 NADPH 
oxidase complex, which mediates the generation of reactive oxygen species to kill invading 
pathogens. Interestingly, although transcription of constituents of the Nox2 NADPH complex 
were not severely affected, we observed the upregulation of Rnf145, a negative regulator of the 
Nox2 complex. Rnf145 has recently been implicated in the proteostasis of the Nox2 complex 
by endoplasmic reticulum-associated degradation [36]. Graham et al., very elegantly 
demonstrated the importance of this factor as negative regulator by showing that ablation of 
Rnf145 in murine macrophages enhance bacterial clearance and rescued the oxidative burst 
defects associated with Ncf4 haplo-insufficiency [36]. A further important observation was that 
ACLF monocytes featured a dampened expression of IRF8, a transcriptional activator of the 
oxidative burst response. IRF8 along with IRF1 and their downstream targets have been  shown 
to be specifically required for the protection against infection [37]. In addition, IRF8 plays a 
critical role in monocyte/macrophage polarization to an inflammatory phenotype and as 
regulator of genes involved in antigen presentation and T cell activation [37,38]. Interestingly, 
the impaired IRF8 expression within ACLF monocytes was associated with lower levels of 
molecules involved in antigen presentation- (HLA, CD74) and T cell co-stimulation (CD80, 
CD86) as well as characteristic markers for classically activated immunostimulatory or 
proinflammatory - M1 monocytes/macrophages (CXCL9, CXCL10, IL-15 and ITGAL). It is 
therefore tempting to speculate that an IRF8-dependent mechanism maybe involved in the 
failure of ACLF monocytes to raise an appropriate oxidative burst- and inflammatory response.  
However, besides hampered pro-inflammatory and anti-bacterial defence mechanisms, ACLF 
monocytes also exhibited elevated expression of markers associated with alternatively activated 
anti-inflammatory/tolerogenic M2 macrophages including IL10, MERTK, CCL22, IL4R, CD36, 
MARCO and CD163. This result is in line with previous studies showing upregulation of 
singular anti-inflammatory parameters in monocytes from ACLF patients [18,19]. Combined, 
our data outline the extent of immune dysfunction within ACLF monocytes and provides 
possible insights in the underlying mechanism governing the susceptibility to infections, as a 
characteristic precipitating event during this syndrome.  
 
Interestingly, similar immunosuppressive features along with metabolic- and epigenetic 
reprogramming have been observed in circulating monocytes from late stage sepsis patients 
[39,40]. This is in sharp contrast to the characteristic overt upregulation of pro-inflammatory 
parameters during acute stages of sepsis that resembled more the expression pattern observed 
in monocytes from decompensated cirrhosis patients [41]. Considering the fact that sepsis is a 
major cause of death in ACLF patients, future investigations aimed at understanding the 
mechanisms underlying immune dysfunction, as well as similarities between sepsis-induced- 
and ACLF-induced immunosuppression, may improve therapeutic strategies [42]. Another 
potential interesting and important line of investigation is how the source of infection may affect 
circulating- and peripheral innate immune cells. Intestinal barrier failure and bacterial 
translocation  through the portal vein has recently been shown to directly affect liver residing 
myeloid cells rendering them  incapable of clearing infection [44,45]. It will therefore be 
intriguing to determine how ACLF monocyte function correlates with the presence of bacteria 
or its components in the circulation as well as with clinical patient data regarding past and 
ongoing infections. 
 
Monocyte/macrophage function is not only controlled at the transcriptional- and 
posttranscriptional level but their metabolic program can also govern their phenotype [33,46]. 
In particular M2 macrophages maintain an intact TCA cycle and favour oxidative metabolism, 
especially fatty acid oxidation, as mode of ATP production.  Additionally, glutamine anabolism 
is particularly elevated in M2 macrophages for the generation of UDP-GlcNAc and 
glycosylation of many characteristic scavenger receptor markers [35,47]. We demonstrate here 
for the first time that monocytes conditioned with ACLF plasma portrayed a clear 
downregulation of key parameters in the glycolytic pathway (including PFKM, PGK1 and 
ENO2) as well as modulation of parameters involved in fatty acid metabolism. Strikingly, 
blocking glutamine synthetase using an inhibitor thereof improved the capacity to clear bacteria 
both in ACLF-plasma conditioned monocytes as well as monocytes derived from ACLF 
patients. Furthermore, we demonstrate that monocytes derived from ACLF patients feature 
elevated expression of enzymes regulating glutamine anabolism (GLUL) and dampened 
expression of enzymes regulating glutamine catabolism (GLS). Underscoring the biological 
relevance of this finding, we detected a positive correlation between GLUL/GLS ratio and 
MELD disease severity scores. Interestingly, in the cancer research field such metabolic 
rewiring of tumour-associated macrophages, through the inhibition of glutamine synthetase, 
has been shown to revert M2 macrophages towards an M1-like phenotype, that promoted 
immunostimulatory and antiangiogenic effects that prevented the development of metastasis 
[48]. Our results are in line with these findings showing decreased IL-10 and elevated TNFα 
production by patient monocytes following inhibition of glutamine synthetase. Glutamine 
synthetase therefore may represent an important checkpoint in the regulation of the 
immunological function of monocytes/macrophages both in cancer as well as in response to 
bacterial infections.  
 
In addition to characterizing the full extent of innate immune dysfunction of monocytes from 
ACLF patients, we highlight a number of possible mechanisms that may explain increased 
susceptibility to infections.  Our data also demonstrates that metabolic programs can be 
manipulated to rescue defective monocyte phagocytic functions. Finally, this work highlights 
the importance of metabolic immunotherapeutic strategies in the treatment of ACLF and it will 
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Figure legends 
Figure 1. Phenotypic and functional analysis of monocyte subsets within patients with 
decompensated cirrhosis or ACLF. Peripheral blood mononuclear cells (PBMCs) were 
isolated and stained for monocyte specific surface markers. A) Flow cytometric analysis of 
classical-, intermediate- and non-classical monocyte frequencies in patients with ACLF (n=15), 
decompensated cirrhosis (Decomp) (n=7) and healthy controls (n=10) (Mean ± SEM; * p<0.05; 
**p<0.01). B) The quantitative median fluorescence intensity (MFI) of HLA-DR surface 
expression on classical-, intermediate- and non-classical monocytes obtained from ACLF 
(n=15), Decomp (n=7) and healthy controls (n=10) (mean ± SEM) (* p<0.05; ** 
p<0.01compared to controls). C) Frequency of intracellular IL-10-positive classical-, 
intermediate- and non-classical monocytes in patients with ACLF (n=4), Decomp (n=4) and 
healthy controls (n=12). The data show mean ± SEM (*, p<0.05).  
 
Figure 2. Immunosuppressive transcriptional profile of monocytes from ACLF patients. 
RNAsequencing was performed on isolated monocytes from ACLF patients (n = 9), 
decompensated cirrhosis patients (Decomp) (n = 4) and healthy controls (n = 5). Differentially 
expressed genes with a 2log fold change > +1 or < -1 and FDR< 0.05 were computed to explore 
patient subgroups. Volcano plots indicate all the up- (red) and downregulated (green) genes 
within monocytes from Decomp compared to controls (A) or ACLF patients compared to 
controls (B). Panel C depicts the comparison of ACLF patients versus Decomp. In addition, the 
top 10 biological processes for the differentially expressed genes were identified and these are 
indicated as circular charts surrounding the volcano plots. The biological processes that were 
upregulated are illustrated in a red color on the right side of the volcano plots while the 
downregulated processes are depicted in a green color to the left of the volcano plots. The size 
of the circle charts correlates with the number of genes per process that were regulated (the 
number thereof is indicated in the middle of the chart). The color intensity of the circle charts 
indicates the significance whereby a biological process were upregulated (dark red = most 
significant) or downregulated (dark green = most significant). Heat maps of proinflammatory 
M1 markers (E) or anti-inflammatory M2 markers (E) selected from the RNAseq data shows 
the close clustering of the monocyte samples within each experimental group. Scale of gene 
expression is indicated by color ranging from low (green) to high (red). 
  
Figure 3. Defective antibacterial mechanisms of monocytes from ACLF patients. Flow 
cytometric analysis of TLR2 (A) and TLR 4 (B) expression on the surface of CD14+CD16- 
monocytes. Flow cytometry data derived from a whole blood phagocytosis and oxidative burst 
assay following E. coli challenge and surface staining for monocyte specific surface markers in 
patients with ACLF (n=13), -decompensated cirrhosis (Decomp) (n=12) and healthy controls 
(n=15). Graphs show the percentage of CD14+CD16- classical monocytes that have internalized 
E. coli bacteria (C) or have produced reactive oxygen species (D). (mean ± SEM; *p<0.05, 
**p<0.01, ***p<0.001). Panel E depicts a schematic representation of components involved in 
monocyte oxidative burst response. The figure indicates potential checkpoints in the activation 
or regulation of events in this pathway. Expression levels of IRF8 (F), PRKCE (G), RNF145 
(H) within monocytes from ACLF patients (n = 8), decompensated cirrhosis patients (Decomp) 
(n = 4) or healthy controls (n = 5) (mean ± SEM; *p<0.05).  
 
Figure 4: In vitro model to mimic monocyte dysfunction in ACLF. Freshly isolated 
CD14+CD16- monocytes from healthy donors were cultured in the presence of normal human 
plasma or ACLF patient plasma (20% v/v) (A). RNAsequencing was performed after a culture 
period of 16 hours to identify differentially expressed genes. Hierarchic clustering of monocytes 
following conditioning with ACLF plasma (ACLF) or normal human plasma (Normal) was 
performed using the expression of a subset of proinflammatory M1 (Panel B)- and anti-
inflammatory M2 (Panel C) genes. The scale is indicated by a color ranging from low (green) 
to high (red). Quantification of pro- and anti-inflammatory parameters from monocytes of 
healthy donors following condition with Normal or ACLF plasma for 16 hours. Relative mRNA 
levels of pro- (D) or anti-inflammatory parameters (E), were determined by means of RT-qPCR 
at the end of the culture period (Mean ± SEM; n = 6). Similarly, protein levels of a selection of 
pro- (F) and anti-inflammatory (G) markers were determined after 16 hours of culture with a 
high-sensitive multiplex immunoassay. Finally, healthy monocytes were cultured in the 
presence of ACLF or normal plasma (20% v/v) and challenged with low doses pHrodo-labeled 




Figure 5. Metabolic reprograming of ACLF monocytes. Schematic representation of glucose 
and glutamine metabolism programs (A). Blocking glutamine synthetase with the 
phamacological inhibitor, methionine sulfoximine (MSO) fuels the TCA cycle (schematic 
representation) (B). The effect of (MSO) on healthy monocyte’s ability to phagocytose bacteria 
under normal plasma or ACLF plasma conditioning.  Monocytes were cultured in the presence 
of ACLF or normal plasma (20% v/v) and treated with MSO (2mM).  Low doses of pHrodo-
labeled E.coli was added to the cells and engulfment was measured with the IncuCyte system. 
The results depict the number of pHrodo-positive monocytes over time (C). The GLUL/GLS 
ratio in monocytes from patients with ACLF compared to monocytes from healthy controls (D). 
The correlation of GLUL/GLS ratio with the MELD scores of patients with ACLF (E). 
Monocytes obtained ACLF patient were treated with or without MSO and challenged with low 
doses of pHrodo-labeled E.coli before measuring engulfment with the IncuCyte system (F). 
Monocytes obtained from ACLF patients were treated with or without MSO and cultured under 
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RNA isolation and qRT-PCR 
RNA was isolated using Trizol (Thermo Fisher Scientific) and the RNeasy Mini Kit (Qiagen, 
Heidelberg, Germany) according the manufactures instructions. RNA quantity and quality was 
measured using a NanoDrop spectrophotometer (Nanodrop Technologies, Wesington, USA) and an 
Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, USA). Samples meeting a RNA integrity 
number criterion of >8 were used for subsequent studies. One microgram of cellular RNA was reverse 
transcribed into cDNA using SuperScript II reverse transcriptase and random hexamer primers 
(Invitrogen/Life Technologies, USA). The PCR reaction was carried out in a mixture that contained 
appropriate sense- and anti-sense primers and a TaqMan MGB probe in Taq-Man Universal PCR Master 
Mixture (Applied Biosystems, Foster City, USA). Beta-2-microglobulin was used as housekeeping 
gene. qRT-PCR amplification and data analysis was performed using the Lightcycler 96 (Roche Applied 
Science, Penzberg, Germany). Each sample was assayed in duplicate. The ΔΔCq method was used to 
determine relative gene expression levels. 
 
Next Generation Sequencing (NGS) and data processing 
NGS was performed on isolated CD14+ cells derived from ACLF patients and healthy controls or from 
CD14+ cells modulated in vitro with ACLF plasma. Briefly, poly-A containing mRNA molecules were 
purified from the total RNA input using poly-T oligo-attached magnetic beads. Standard Illumina 
unstranded poly-A enriched libraries were prepared and sequencing thereof (paired-end 75 bp reads) 
occurred on an Illumina NextSeq 500 half flow cell to a depth of 4.1-7.1 million reads per sample (in 
quadruple). After preprocessing, reads were aligned with STAR 2.4.1d to the reference genome of Homo 
sapiens (GRCh37.73) and counted with featureCounts 1.4.6 (1, 2). With the EdgeR 3.8.6 package of 
Bioconductor (3), generalized linear model (GLM) was fitted against the normalized counts (4).  
 
Data analysis 
To identify the differentially expressed genes between CD14+ cells of ACLF patients compared to 
healthy controls, unpaired analysis was performed. To identify significantly changed gene expression 
in isolated CD14+ cells that were cultured in the presence of serum we performed paired analysis. The 
individual results were combined, the average computed and the resulting p-values of the Limma and 
EdgeR packages were corrected for multiple testing with Benjamini–Hochberg to control false discovery 
rate for paired and unpaired analysis (5). A gene was considered differentially expressed if a 2log fold 
change >+1 or <-1 and a corrected p < 0.05. We used this in silico analysis to investigate the biological 
processes and KEGG pathways involved in ACLF. The genes differentially expressed in one direction 
in patients or after in vitro modulation were used as input in the software packet Webgestalt 
(http://www.webgestalt.org/). This program is designed for functional genomic, proteomic and large-
scale genetic studies. The software proposes, based on strict statistical testing, likely functional 
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networks, including: 1) GO (geneontology) Biological Process that are defined as operations or sets of 
molecular events with a defined beginning and end, pertinent to the functioning of integrated living 
units: cells, tissues, organs, and organisms (http://geneontology.org/) and 2) KEGG PATHWAYs, 
which is a collection of manually drawn pathway maps representing our knowledge on the molecular 
interaction and reaction networks (http://www.genome.jp/kegg/pathway.html). Additional analysis of 
molecular interactions was done using STRING 10.0 algorithmic, a software that can predict interactions 
based on literature and other electronic information. The program visualizes reported gene interactions 
whereby the lines indicate the strength of association (6). Notably, because the number of genes is 
mostly a fraction of all the genes assigned to a specific KEGG pathway, computer analysis can map the 
same gene sets to different molecular processes (having mutual genes but different function). 
Notwithstanding, further evaluation and data interpretation by the researcher is always required to 
allow integration with the biological setup. Further of importance is that we applied paired analysis in 
order to compensating for the biological differences that exists between individual healthy donors 
(natural variation present already at the time of monocyte isolation). Notably, with the hierarchic 
cluster analysis of in vitro gene expression this biological variation could not be compensated for in 
the same way as in paired analysis. 
 
  




Supplemental Table 1: Clinical characteristics of patients admitted with decompensated 
cirrhosis and ACLF 
 





Age (yrs) 59 [46-68] 54 [49-61] ns 
Gender, Male (%) (10(53%)) (12(55%)) ns 
Total bilirubin (mg/dl) 3 [2-5]† 15 [11-26]† p<0.001 
ALT (U/L) 26 [16-43]† 42 [30-82]† p=0.002 
AST (U/L) 56 [29-85]† 98 [61-220]† p<0.001 
ALP (U/L) 109 [91-162] 136 [122-188] p=0.002 
GGT (U/L) 70 [24-157] 106 [56-245] p<0.001 
Albumin (g/dl) 32 [26-34] 28 [25-32] ns 
Creatinine (mg/dl) 1.0 [0.8-1.6] 1.2 [0.8-1.7] p=0.008 
Platelet count (x109/L) 143 [88-188]† 83 [57-127]† p=0.01 
INR 1.6 [1.3-2.3]† 2.3 [2.1-2.8]† p<0.001 
MELD 16 [9-24]† 28 [22-35]† p<0.001 
Child-Pugh 10 [8-12]† 12 [11-12]† p<0.001 
Maddrey 







Ascites (n(%)) (19(100%)) (18(82%)) p<0.001 
Encephalopathy (n(%)) (10(53%)) (15(68%)) p=0.002 
Renal failure (n(%)) (7(37%)) (9(40%)) p=0.03 
White cell count (x109/L) 7 [5-10] 10 [7-14] p=0.03 
CRP (mg/L) 13 [8-37] 33 [16-46] ns 
Blood culture positive (n(%))  (2(11%)) (8(36%)) ns 
Urine culture positive (n(%)) (3(16%)) (1(5%)) ns 
Infiltrates on chest X-ray (n(%)) (1(5%))† (11(50%))† p=0.002 
Antibiotic treatment (n(%)) (11(58%)) (19(86%)) p<0.001 
Steroid treatment (n(%)) (0(0%))† (14(64%))† p<0.001 
30-day mortality (n(%)) (0(0%)† (5(23%))† p=0.007 
Admitted to ICU (n(%)) (6(32%)) (13(59%)) p=0.005 
Data are presented as mean±SEM, median [IQR] or number of patients (%).†Decompensated vs ACLF p<0.05.  
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Supplemental Table 2: Clinical characteristics of patients included for monocyte 
transcriptional and functional analysis 
 
Clinical parameter Decompensated 
cirrhosis (n=4) 
ACLF grade 2 
(n=13) 
p-value 
Age (yrs) 66 [55-69] 57 [53-61] ns 
Gender, Male (%) (3(75%)) (10(77%)) ns 
Total bilirubin (mg/dl) 5 [4-5] 17 [10-23] p=0.002 
ALT (U/L) 21 [17-24] 47 [23-73] p=0.05 
AST (U/L) 43 [27-65] 124 [41-202] p=0.04 
ALP (U/L) 119 [77-267] 121 [106-192] ns 
GGT (U/L) 127 [16-635] 91 [30-264] ns 
Albumin (g/dl) 29 [27-32] 30 [23-36] ns 
Creatinine (mg/dl) 0.7 [0.6-1.0] 0.9 [0.7-1.5] ns 
Platelet count (x109/L) 82 [59-343] 93 [64-157] ns 
INR 1.9 [1.2-2.7] 2.6 [2.0-3.0] ns 
MELD 15 [11-25] 29 [24-32] p<0.001 
Maddrey 27  75 [56-147] - 
Ascites (n(%)) (4(100%)) (11(84%)) - 
Encephalopathy (n(%)) (3(75%)) (8(62%)) ns 
Renal dysfunction (n(%)) (0(0%)) (6(46%)) - 
White cell count (x109/L) 6 [4-7] 8 [7-11] ns 
CRP (mg/L) 11 [4-30] 24 [10-38] ns 
Blood culture positive (n(%))  - (2(15%)) - 
Antibiotic treatment (n(%)) (0(0%)) (0(0%)) - 
Steroid treatment (n(%)) (0(0%))† (0(0%))† - 
30-day mortality (n(%)) (0(0%)† (10(77%))† - 
Data are presented as mean±SEM, median [IQR] or number of patients (%).†ACLF vs Decompensated p<0.05  
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Supplementary Figure 1: Quantification of circulating cytokines and chemokines in patients with 
alcoholic liver disease. Cytokines and chemokines were measured in plasma samples collected from 
patients with ACLF (n=18), decompensated liver disease (n=9) and healthy controls (n=7) using 
MSDmesocale multiplex immunoassays. The results are displayed as Median and IQR (p > 0.05 was 




H. Korf et al: Reviving monocyte function in ACLF (Supplement) 
7 
 
Supplementary Figure 2: Hierarchic clustering of gene expression of KEGG pathway hsa04612: 
antigen processing and presentation. Monocytes were isolated from control patients (n=5), Decomp 
(n=4) and ACLF (n=9) and NGS was performed. Clustering of pathway assigned genes resulted in 3 















Supplementary Figure 3: Immunohistological quantification of MerTK-positive cells in the liver 
tissue of ACLF patients. Formalin-fixed paraffin-embedded liver biopsies or -explants were stained 
with a primary antibody directed against MerTK, followed by a standard horseradish peroxidase 
visualization step with 3,3'-diaminobenzidine. Representative light microscopy images of MerTK-
positive cells in decompensated- (A) and ACLF (B) patients. Black arrows indicate examples of MerTK 
positive cells. The number of MerTK cells was quantified and represented as a histological score 
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p = 0.004 
p = 0.014 
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Supplementary Figure 4: Monocytes from four different healthy donors were cultured in the presence 
of ACLF or normal plasma (20% v/v) and challenged with pHrodo-labeled S. aureus at a previously 
optimized host:bacterium ratio. The frequency of monocytes that engulfed the bioparticles was 
evaluated using the IncuCyte system over a period of 24 hours.  
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Supplementary Figure 5: Quantification of key metabolic parameters from monocytes of healthy 
donors. Isolated CD14+ monocytes were cultured in the presence or absence of ACLF plasma for 16 
hours as described in the methods section. Relative mRNA levels of or metabolic parameters were 
determined by means of RT-qPCR at the end of the culture period. (Mean ± SEM; n = 6). 
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